Company profile: Acepodia
1.1 - Company Overview
Company description
- Provider of cancer cell therapies and platform technology, including ACC (Antibody-Cell Conjugation) to attach tumor-targeting antibodies to immune cells without genetic engineering; off-the-shelf allogeneic γδ2 T cell therapies; and ACC-γδ2 T cell candidates ACE1831 (CD20), ACE2016 (EGFR), and ACE1708 (PD-L1).
Products and services
- γδ2 T cell therapy: Off-the-shelf cell therapies using γδ2 T cells that recognize and attack cancer cells while coordinating broad antitumor immune responses for robust, multi-target activity
- ACC (Antibody-Cell Conjugation) technology: Non-genetically engineered platform that attaches tumor-targeting antibodies to immune cells, enabling creation of cell therapies with precise antigen targeting without genomic alteration
- ACE1831: CD20-directed ACC-γδ2 T cell therapy that targets CD20-expressing tumors, integrating antibody guidance with γδ2 T-cell attack to treat cancer
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Acepodia
Delcath Systems
HQ: United States
Website
- Description: Provider of interventional oncology therapies for metastatic liver cancer, including HEPZATO KIT for adult patients with metastatic uveal melanoma using a hepatic delivery system; the CHEMOSAT Hepatic Delivery System for melphalan for percutaneous hepatic perfusion to treat liver cancers; and Percutaneous Hepatic Perfusion, a minimally invasive procedure delivering high-dose chemotherapy directly to the liver while isolating the organ from the body’s circulatory system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Delcath Systems company profile →
Imvaq Therapeutics
HQ: United States
Website
- Description: Provider of innovative cancer immunotherapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imvaq Therapeutics company profile →
Salmedix
HQ: United States
Website
- Description: Provider of oncology drug development focused on hematologic malignancies (blood cancers). Primary product SDX-105 is marketed by healthcare professionals in Germany for several types of blood cancers; conducts Phase II clinical trials for SDX-105 in the U.S. and Canada.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Salmedix company profile →
Theragenics
HQ: United States
Website
- Description: Provider of brachytherapy seed and surgical products. Offers Palladium-103 (TheraSeed) and Iodine-125 (AgX100) seeds for precise tumor radiation and localization (RSL), gold fiducial markers; wound closure products (sutures, needles), specialty needles; vascular and non-vascular access devices (introducers, catheters, guidewires); and consultancy for minimally invasive medical device design and manufacture.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theragenics company profile →
Fusion Pharmaceuticals
HQ: Canada
Website
- Description: Provider of clinical-stage radiopharmaceuticals and targeted alpha therapies for oncology, leveraging deep radiochemistry and Fast-Clear Linker Technology to improve safety. Pipeline includes FPI-2265 targeting PSMA in prostate cancer (Phase 2), FPI-1434 targeting IGF-1R, and FPI-2059 targeting NTSR1. Offers manufacturing expertise to build commercial supply chains.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fusion Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Acepodia
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Acepodia
2.2 - Growth funds investing in similar companies to Acepodia
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Acepodia
4.2 - Public trading comparable groups for Acepodia
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →